Lates News

According to Jieming AI News, Dongwu Securities released a research report on September 6th, giving a buy rating to Maiwei Biology (688062.SH). The reasons for the rating mainly include: 1) 9MW3811, an IL-11 monoclonal antibody developed independently by Maiwei Biology, is at the forefront of global progress and has attracted the attention of Silicon Valley giants; 2) The anti-aging mechanism of 9MW3811 is clear, and there is potential for expansion into pathological scar indications in the future; 3) There are multiple heavyweight pipelines with abundant reserves. (Daily Economic News)